140 related articles for article (PubMed ID: 34083303)
1. Prognostic Significance of HER2 Expression for Gastric Cancer With Clinically Para-aortic Lymph Node Metastasis.
Arigami T; Matsushita D; Okubo K; Sasaki K; Tsuruda Y; Kita Y; Mori S; Yanagita S; Uenosono Y; Kurahara H; Ohtsuka T
Anticancer Res; 2021 Jun; 41(6):3099-3107. PubMed ID: 34083303
[TBL] [Abstract][Full Text] [Related]
2. The clinicopathological parameters and prognostic significance of HER2 expression in gastric cancer patients: a meta-analysis of literature.
Lei YY; Huang JY; Zhao QR; Jiang N; Xu HM; Wang ZN; Li HQ; Zhang SB; Sun Z
World J Surg Oncol; 2017 Mar; 15(1):68. PubMed ID: 28327158
[TBL] [Abstract][Full Text] [Related]
3. Clinical significance of circulating tumor cells in the response to trastuzumab for HER2-negative metastatic gastric cancer.
Matsushita D; Uenosono Y; Arigami T; Yanagita S; Okubo K; Kijima T; Miyazono F; Hamanoue M; Hokita S; Nakashima S; Ohtsuka T; Natsugoe S
Cancer Chemother Pharmacol; 2021 Jun; 87(6):789-797. PubMed ID: 33641065
[TBL] [Abstract][Full Text] [Related]
4. [The Case of HER2 Positive Advanced Gastric Cancer with Para-Aorta Lymph Node Recurrence Responding to Capecitabine plus CDDP plus Trastuzumab Chemotherapy].
Hashimoto I; Murakami H; Arisaka S; Sugawara Y; Segami K; Takagawa R; Hayashi T; Shimada K; Hirakawa S; Hasegawa S; Fukushima T; Ike H; Imada T; Rino Y; Masuda M
Gan To Kagaku Ryoho; 2017 Nov; 44(12):1455-1457. PubMed ID: 29394666
[TBL] [Abstract][Full Text] [Related]
5. Is her-2 status in the primary tumor correlated with matched lymph node metastases in patients with gastric cancer undergoing curative gastrectomy?
Selcukbiricik F; Erdamar S; Buyukunal E; Serrdengecti S; Demirelli F
Asian Pac J Cancer Prev; 2014; 15(24):10607-11. PubMed ID: 25605147
[TBL] [Abstract][Full Text] [Related]
6. [A case of HER2-positive advanced gastric cancer successfully treated via capecitabine, cisplatin, and trastuzumab combination chemotherapy].
Endo S; Yamada T; Okuyama M; Hiraoka K; Konishi K; Kim C; Nakagawa T; Takeda K; Ueda Y; Matsumoto K; Nishikawa K; Nishijima J
Gan To Kagaku Ryoho; 2015 Mar; 42(3):359-61. PubMed ID: 25812508
[TBL] [Abstract][Full Text] [Related]
7. Loss of HER2 positivity after anti-HER2 chemotherapy in HER2-positive gastric cancer patients: results of the GASTric cancer HER2 reassessment study 3 (GASTHER3).
Seo S; Ryu MH; Park YS; Ahn JY; Park Y; Park SR; Ryoo BY; Lee GH; Jung HY; Kang YK
Gastric Cancer; 2019 May; 22(3):527-535. PubMed ID: 30386954
[TBL] [Abstract][Full Text] [Related]
8. Prognostic Factors in Patients with Advanced HER2-Positive Gastric Cancer Treated with Trastuzumab-Based Chemotherapy: a Cohort Study.
Marshall S; Wakatsuki T; Takahari D; Matsushima T; Ishizuka N; Nakayama I; Osumi H; Ogura M; Ichimura T; Shinozaki E; Chin K; Yamaguchi K
J Gastrointest Cancer; 2023 Jun; 54(2):475-484. PubMed ID: 35435573
[TBL] [Abstract][Full Text] [Related]
9. Impact of HER2 expression on outcome in gastric cancer patients with liver metastasis.
Jiang H; Li Q; Yu S; Yu Y; Wang Y; Li W; Cui Y; Liu T
Clin Transl Oncol; 2017 Feb; 19(2):197-203. PubMed ID: 27324991
[TBL] [Abstract][Full Text] [Related]
10. A prognostic scoring system for conversion surgery after trastuzumab-based chemotherapy for human epidermal growth factor receptor 2-positive advanced gastric cancer.
Arigami T; Matsushita D; Okubo K; Shimonosono M; Sasaki K; Tsuruda Y; Kita Y; Tanabe K; Mori S; Yanagita S; Uenosono Y; Nakajo A; Kurahara H; Ohtsuka T
Surg Today; 2022 Dec; 52(12):1721-1730. PubMed ID: 35543754
[TBL] [Abstract][Full Text] [Related]
11. [A case of para-aortic lymph node metastasis from gastric cancer treated with chemoradiotherapy].
Okada K; Oka Y; Soma I; Nakane S; Higaki N; Murakami M; Hayashida H; Ichihara T; Sakon M
Gan To Kagaku Ryoho; 2013 Nov; 40(12):2286-8. PubMed ID: 24394087
[TBL] [Abstract][Full Text] [Related]
12. HER2-positive patients receiving trastuzumab treatment have a comparable prognosis with HER2-negative advanced gastric cancer patients: a prospective cohort observation.
Qiu MZ; Li Q; Wang ZQ; Liu TS; Liu Q; Wei XL; Jin Y; Wang DS; Ren C; Bai L; Zhang DS; Wang FH; Li YH; Xu RH
Int J Cancer; 2014 May; 134(10):2468-77. PubMed ID: 24155030
[TBL] [Abstract][Full Text] [Related]
13. Pathologic Response of HER2-positive Gastric Cancer to Trastuzumab-based Chemotherapy.
Urabe M; Ushiku T; Seto Y; Fukayama M
Am J Surg Pathol; 2016 Oct; 40(10):1326-33. PubMed ID: 27259008
[TBL] [Abstract][Full Text] [Related]
14. Significance of para-aortic lymph node dissection in advanced gastric cancer.
Kunisaki C; Shimada H; Yamaoka H; Wakasugi J; Takahashi M; Akiyama H; Nomura M; Moriwaki Y
Hepatogastroenterology; 1999; 46(28):2635-42. PubMed ID: 10522056
[TBL] [Abstract][Full Text] [Related]
15. Evaluation of HER2 protein expression in gastric carcinomas: comparative analysis of 1,414 cases of whole-tissue sections and 595 cases of tissue microarrays.
Kim KC; Koh YW; Chang HM; Kim TH; Yook JH; Kim BS; Jang SJ; Park YS
Ann Surg Oncol; 2011 Oct; 18(10):2833-40. PubMed ID: 21468783
[TBL] [Abstract][Full Text] [Related]
16. Clinical significance of intratumoral HER2 heterogeneity on trastuzumab efficacy using endoscopic biopsy specimens in patients with advanced HER2 positive gastric cancer.
Yagi S; Wakatsuki T; Yamamoto N; Chin K; Takahari D; Ogura M; Ichimura T; Nakayama I; Osumi H; Shinozaki E; Suenaga M; Fujisaki J; Ishikawa Y; Yamaguchi K; Namikawa K; Horiuchi Y
Gastric Cancer; 2019 May; 22(3):518-525. PubMed ID: 30328533
[TBL] [Abstract][Full Text] [Related]
17. Risk factors for metastasis to para-aortic lymph nodes in gastric cancer: a single institution study in China.
Wang L; Liang H; Wang X; Li F; Ding X; Deng J
J Surg Res; 2013 Jan; 179(1):54-9. PubMed ID: 23040213
[TBL] [Abstract][Full Text] [Related]
18. Association of HER2 status with prognosis in gastric cancer patients undergoing R0 resection: A large-scale multicenter study in China.
Shen GS; Zhao JD; Zhao JH; Ma XF; Du F; Kan J; Ji FX; Ma F; Zheng FC; Wang ZY; Xu BH
World J Gastroenterol; 2016 Jun; 22(23):5406-14. PubMed ID: 27340357
[TBL] [Abstract][Full Text] [Related]
19. Survival analysis based on human epidermal growth factor 2 status in stage II-III gastric cancer.
Cho JH; Lim JY; Cho JY
World J Gastroenterol; 2017 Nov; 23(41):7407-7414. PubMed ID: 29151694
[TBL] [Abstract][Full Text] [Related]
20. Prognostic value of phosphorylated HER2 in HER2-positive breast cancer patients treated with adjuvant trastuzumab.
Kurebayashi J; Kanomata N; Yamashita T; Shimo T; Mizutoh A; Moriya T; Sonoo H
Breast Cancer; 2015 May; 22(3):292-9. PubMed ID: 23749689
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]